Contribute Try STAT+ Today

A new cholesterol-lowering medication manufactured by Esperion Therapeutics was approved by the Food and Drug Administration on Friday, a decision that will allow the company to test whether price is the biggest barrier to new heart medications on the market.

Heart drugs have had a tough go of it in recent years. Repatha and Praluent, expected to be multibillion sellers, instead saw sales stagnate. Their makers took the unusual step of cutting the drugs’ prices by 60%. Entresto, a Novartis heart failure drug, had a slow start before sales took off. But now there is broadened interest. Amarin expects sales of its fish-oil-derived pill, Vascepa, of upwards of $650 million this year. And, early this year, Novartis spent $9.7 billion to buy The Medicines Company, which is developing a long-acting cholesterol lowering medicine. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • it sounds like no data when added to a statin, and of course they don’t have CV events outcomes data (no one does at approval), so this is just a treatment for people who can’t tolerate a statin. And they’ll probably need to fail Zetia (ezetimibe) too. this is not competing with the injections – it competes with generic statins and ezetimibe.
    Niche drug.

    • upon additional reading, this does have add-on to statin data. Based on this, I rescind my previous comment – there is clearly significant potential. However even a 1% incidence of ruptured tendon is going to keep this drug in reserve. That is not a minor safety risk.

Comments are closed.